Association Between Functional Outcomes of Stroke Patients Receiving Mechanical Thrombectomy and CT Perfusion Imaging Acquisition

Objective: Functional outcomes of Mechanical thrombectomy (MT) in stroke patients with CT perfusion (CTP+) imaging versus without (CTP−) Background: MT trials in the early window ( Design/Methods: We used data from 2 cohorts (New York University (NYU) and Blood Pressure After Endovascular Stroke Therapy (BEST)) and compared functional outcomes among sites that performed CTP for all patients versus those who did not. Good functional outcome was defined as a mRS of 0–2 at 90 days, or, if unavailable, a discharge mRS of 0–3. Binary logistic regression was used to predict the odds of good outcomes adjusting for age, NIHSS, recanalization grade, ASPECTS and LKN to reperfusion Results: There were 407 patients in the NYU (100 CTP+; 307 CTP−) and 135 patients in the BEST cohort (50 CTP+; 85 CTP−). Obtaining CTP was not associated with increased likelihood of good functional outcomes in NYU (adjusted OR (aOR) 1.41, 95%CI=0.53–3.76; p=0.49), BEST (aOR 1.28, 95%CI=0.27–6.17; p=0.76) and the pooled cohort (aOR 1.32, 95%CI=0.61–2.89; p=0.48) nor odds of symptomatic intracerebral hemorrhage in the pooled cohort (aOR 1.95, 95%CI=0.43–8.88; p=0.39). In addition, obtaining CTP was not associated with improved outcomes in the 6–24 hour window patients (n=295; aOR 1.69, 95%CI=0.42–4.53; p=0.61). Time from arrival to groin puncture was not significantly different between CTP+ and CTP− (72 min versus 82 min; p=0.17) Conclusions: In patients undergoing MT, CTP acquisition did not impact good functinal outcomes. Additionally, patients who received CTP had similar MT treatment times compared to those who did not receive it. Larger studies with set selection criteria are needed to determine how CTP acquisition affects clinical outcomes in MT patients Disclosure: Dr. Agarwal has nothing to disclose. Dr. Mistry has nothing to disclose. Dr. Scher has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Sanger has nothing to disclose. Dr. Humbert has nothing to disclose. Dr. Ishida has nothing to disclose. Dr. Torres has nothing to disclose. Dr. Rostanski has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Arcot has nothing to disclose. Dr. Turkel-Parrella has nothing to disclose. Dr. Farkas has nothing to disclose. Dr. Raz has nothing to disclose. Dr. Gordon has nothing to disclose. Dr. Riina has nothing to disclose. Dr. Shapiro has nothing to disclose. Dr. Tanweer has nothing to disclose. Dr. Nossek has nothing to disclose. Dr. Nelson has nothing to disclose. Dr. Lord has nothing to disclose. Dr. Vezina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz Pharma Canada. Dr. Yaghi has nothing to disclose.